Abilita Bio

Abilita Bio is an innovation-driven biotechnology company focused on discovering and developing therapeutic antibodies targeting the most challenging and medically significant multi-transmembrane proteins, including G protein-coupled receptors (GPCRs) and ion channels. Abilita Bio is building a robust and fully integrated discovery platform that leverages multiple cutting-edge technologies and approaches to generate a rich pipeline of unique assets. The company’s proprietary technology utilizes directed evolution to identify Enhanced Modified Protein (EMP) variants, which can overcome these challenges while maintaining the relevant protein structure.